Wang et al. demonstrated that VEGFR-1 CAR-T cells can be a promising solution to break the resistance to traditional anti-angiogenic therapies, with higher efficacy than strategies blocking separately cancer growth or angiogenesis. This evidence concerns the gene FLT1 and cancer.